source
- Weekly roundup highlights Biohaven’s challenge to Eli Lilly and industry competition with ChinaThe latest Endpoints Weekly issue focuses on a series of recent deals across the biotech sector, offering readers a snapshot of market activity. Among the items highlighted is Biohaven’s strategic…
- FDA rejects Hengrui-Elevar liver cancer drug combo for third time over manufacturing issuesFDA has again turned down a liver cancer drug combination from Jiangsu Hengrui Pharmaceuticals and Elevar Therapeutics. This is the third rejection in roughly two years, with the agency citing per…